Clinical Trials Browser

Terminated × Ovarian Neoplasms × Sorafenib × Clear all

NCT00526799 2016-03-03

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Phase 1/2 Terminated

30 enrolled 16 charts

Ovarian Neoplasms

NCT00522301 2016-02-29

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Phase 2 Terminated

6 enrolled 5 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms